Ekso Bionics' Q3 revenue up on high margin sales

Chronoscale

28/10/2025 20:22

Overview

Ekso Bionics Q3 2025 revenue grew 2% yr/yr but missed analyst expectations

Company's gross margin rose to 60.3%

Net loss improved 31% yr/yr to $1.4 mln

Outlook

Company exploring strategic transactions, including potential acquisition or sale of business

Ekso Bionics to continue executing growth strategy

Result Drivers

HIGH MARGIN SALES - Increase in gross profit driven by high margin Enterprise Health sales

LOWER DEVICE COSTS - Gross margin improvement attributed to lower device costs and improved service margins

COST MANAGEMENT - Decrease in sales and marketing expenses due to lower payroll expense from the receipt of the Employee Retention Credit

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$4.22 mln
$4.35 mln (2 Analysts)
Q3 Net Income
-$1.42 mln
Q3 Operating Expenses
$3.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Ekso Bionics Holdings Inc is $34.75, about 85.8% above its October 27 closing price of $4.92

Press Release: ID:nGNX6wNTJn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)